Heli Gao

List of Publications by Year
in descending order

26	739	840776	526287
papers	citations	11 h-index	27 g-index

30	30	30	1439
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Methylation-mediated silencing of the miR-124 genes facilitates pancreatic cancer progression and metastasis by targeting Rac1. Oncogene, 2014, 33, 514-524.	5.9	198
2	Wnt activation protects against neomycin-induced hair cell damage in the mouse cochlea. Cell Death and Disease, 2016, 7, e2136-e2136.	6.3	120
3	Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma. British Journal of Surgery, 2016, 103, 1189-1199.	0.3	98
4	Cavin-1 is essential for the tumor-promoting effect of caveolin-1 and enhances its prognostic potency in pancreatic cancer. Oncogene, 2014, 33, 2728-2736.	5.9	60
5	Novel recurrence risk stratification of resected pancreatic neuroendocrine tumor. Cancer Letters, 2018, 412, 188-193.	7.2	42
6	Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21. Cancers, 2021, 13, 3678.	3.7	37
7	The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma . Cancer Management and Research, 2019, Volume 11, 3327-3337.	1.9	26
8	Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma. Experimental Hematology and Oncology, 2020, 9, 28.	5.0	21
9	Carbohydrate antigen 19â€‘9 as a prognostic biomarker in pancreatic neuroendocrine tumors. Oncology Letters, 2017, 14, 6795-6800.	1.8	20
10	Prognostic value of Î³â€glutamyltransferaseâ€toâ€albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery. Cancer Medicine, 2019, 8, 572-584.	2.8	18
11	Research progress and design optimization of CARâ€T therapy for pancreatic ductal adenocarcinoma. Cancer Medicine, 2019, 8, 5223-5231.	2.8	12
12	The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. Journal of Translational Medicine, 2021, 19, 301.	4.4	12
13	Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer. EBioMedicine, 2022, 79, 104016.	6.1	12
14	Revised nodal stage for pancreatic neuroendocrine tumors. Pancreatology, 2017, 17, 599-604.	1.1	11
15	Imaging features of intracranial psammomatous meningioma. Journal of Neuroradiology, 2017, 44, 395-399.	1.1	10
16	High levels of LDL-C combined with low levels of HDL-C further increase platelet activation in hypercholesterolemic patients. Brazilian Journal of Medical and Biological Research, 2015, 48, 167-173.	1.5	9
17	Serum level of CCL2 predicts outcome of patients with pancreatic cancer. Acta Gastro-Enterologica Belgica, 2020, 83, 295-299.	1.0	7
18	Distinct clinicopathological and prognostic features of insulinoma with synchronous distant metastasis. Pancreatology, 2019, 19, 472-477.	1.1	6

#	Article	IF	Citations
19	The distinctive characteristics of the micro-vasculature and immune cell infiltration in cystic pancreatic neuroendocrine tumors. Journal of Endocrinological Investigation, 2021, 44, 1011-1019.	3.3	4
20	Patterns and predictors of pancreatic neuroendocrine tumor prognosis: Are no two leaves alike?. Critical Reviews in Oncology/Hematology, 2021, 167, 103493.	4.4	4
21	Pevonedistat Suppresses Pancreatic Cancer Growth via Inactivation of the Neddylation Pathway. Frontiers in Oncology, 2022, 12, 822039.	2.8	4
22	Evaluation of two intensive care models in relation to successful extubation after cardiac surgery. Medicina Intensiva, 2020, 44, 27-35.	0.7	2
23	A randomized phase II study of gemcitabine (G) plus the cardiac glycoside huachansu (H) in the treatment of patients with locally advanced (LAPC) or metastatic pancreatic cancer (MPC).. Journal of Clinical Oncology, 2011, 29, 284-284.	1.6	2
24	Sequential Capecitabine/Temozolomide (CAPTEM) and Sunitinib Treatment in Patients with Metastatic Well-differentiated G1/G2 Pancreatic Neuroendocrine Tumors. Endocrine Practice, 2021, , .	2.1	1
25	The optimal duration of capecitabine plus temozolomide in patients with wellâ€differentiated pancreatic NETsÂwith or without maintenance therapy. Journal of Neuroendocrinology, 2022, 34, e13112.	2.6	1
26	PO-1019â€…Clinical Characteristics And Risk Factors Of Severe Respiratory Syncytial Virus-associated Acute Lower Respiratory Tract Infections In Hospitalised Infants. Archives of Disease in Childhood, 2014, 99, A583.1-A583.	1.9	0